Biosplice Therapeutics has raised $898M across 4 funding rounds. The company is valued at $12B (post-money).
Biosplice Therapeutics closed a $120 million Series D equity financing round in April 2021, led by Eventide Asset Management and aMoon, to advance its alternative splicing platform.
4 funding rounds, the latest highlighted.
Biosplice Therapeutics was founded in 2008, United States.
Company was known as Samumed at the time; exact month not found. $220M raised.
Reported by STAT as 'two years later' after the 2016 round; exact month not found. $438M raised.
A primary round — the company sells new shares to investors it selects. $120M raised.
No filing has been made.
4 dated rounds, newest first.
aMoonLEADFFortuna HoldingsAaMoon FundVVerition Fund ManagementIInter IKEA GroupVVickers Venture PartnersSSymBiosis IIPPlutus Investment Group
Sands CapitalThe closest biopharmaceutical — regenerative medicine / alternative pre-mrna splicing therapeutics peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Biosplice Therapeutics is a private company; its shares do not trade on a public exchange.
The last valuation is $12B.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
